Edition:
India

Bellerophon Therapeutics Inc (BLPH.OQ)

BLPH.OQ on NASDAQ Stock Exchange Global Market

2.24USD
19 Jan 2018
Change (% chg)

$0.06 (+2.75%)
Prev Close
$2.18
Open
$2.23
Day's High
$2.25
Day's Low
$2.17
Volume
24,001
Avg. Vol
60,283
52-wk High
$2.71
52-wk Low
$0.61

Select another date:

Wed, Jan 3 2018

BRIEF-Bellerophon Says First Patient Enrolled In Phase 2B Study Evaluating Inopulse For Treating Pulmonary Hypertension

* BELLEROPHON-FIRST PATIENT ENROLLED IN PHASE 2B STUDY EVALUATING INOPULSE FOR TREATING PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE

BRIEF-Bellerophon Appoints Ted Wang To Its Board Of Directors

* BELLEROPHON APPOINTS TED WANG, PH.D., OF PUISSANCE CAPITAL MANAGEMENT, TO ITS BOARD OF DIRECTORS

BRIEF-Bellerophon Therapeutics reports Q3 loss per share $0.22

* Bellerophon provides business update and reports third quarter 2017 financial results

BRIEF-Bellerophon Therapeutics says selling stockholders may offer, resell up to 38.9 mln shares - SEC filing

* Bellerophon Therapeutics Inc files to say selling stockholders may offer and resell up to 38.9 million shares of co's common stock - SEC filing

BRIEF-Bellerophon announces $23 million private placement

* Bellerophon Therapeutics Inc - ‍financing was led by Puissance Capital Management and Venrock Healthcare Capital Partners​

BRIEF-Bellerophon announces positive top line Phase 2 data of INOpulse

* Bellerophon announces positive top line Phase 2 data of INOpulse for treatment of Pulmonary Hypertension associated with Chronic Obstructive Pulmonary Disease

BRIEF-Bellerophon reports Q2 loss per share $0.12

* Bellerophon reports second quarter 2017 financial results and provides business update

BRIEF-Bellerophon announces FDA agreement on phase 2B study design for Inopulse

* Bellerophon announces FDA agreement on phase 2B study design for Inopulse in pulmonary hypertension associated with interstitial lung disease (PH-ILD)

Select another date: